MedTrace Logo

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

NCT05846035 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-05-06

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence. Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .

Conditions

  • Hepatocellular Carcinoma Patients

Interventions

DIAGNOSTIC_TEST

Triphasic C.T abdomen and pelvis

for cirrhotic patients to ensure hepatocellular carcinoma

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05846035 on ClinicalTrials.gov